^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tozaride (Rhenium (Re) 188 P2045)

    i
    Other names: rhenium-188 P2045, Rhenium (Re) 188 P2045, rhenium-188 P 2045, BAY-865284, P2045, Re-188 P 2045, Rh-188 P2045
    Associations

    News

    Trials
    Company:
    Andarix
    Drug class:
    Ionizing radiation emitter, SSTR2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    6ms
    Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104). (PubMed, Cell Rep Med)
    Here, we report interim results of a Simon's two-stage design, phase 2 trial using neoadjuvant sintilimab with carboplatin and nab-paclitaxel in resectable EGFR-mutant NSCLC. Informed circulating tumor DNA (ctDNA) detection in EGFR-mutant NSCLC could help identify patients nonresponsive to neoadjuvant immunochemotherapy. These findings provide supportive data for the utilization of neoadjuvant immunochemotherapy and insight into immune resistance in EGFR-mutant NSCLC.
    P2 data • Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CCR8 (C-C Motif Chemokine Receptor 8)
    |
    carboplatin • Tyvyt (sintilimab) • albumin-bound paclitaxel • Tozaride (Rhenium (Re) 188 P2045)